

Table S8: Treatment Effect on Change in Urine Protein and on Clinical Outcome (ESRD, Doubling and Death)

Study Number	Treatment effect on Proteinuria			R ²	Treatment effect on Clinical Outcome			Ratio of treatment effect on the Clinical endpoint vs. treatment effect on change in UP
	GMR in UP in intervention	GMR in UP in control	GMR comparing intervention to control (95% CI) ^a		Events Treatment	Events Control	HR (95% CI)	
A1	0.77 (0.44, 1.42)	0.82 (0.45, 1.50)	0.95 (0.81, 1.11)	0.001	116	142	0.80 (0.63, 1.02)	0.85 (0.63, 1.89)
A2	0.70 (0.56, 1.00)	1.23 (0.94, 1.64)	0.57 (0.42, 0.76)	0.121	11	13	0.92 (0.41, 2.08)	1.62 (0.62, 1.86)
A3	0.73 (0.52, 1.00)	0.76 (0.60, 1.00)	0.95 (0.66, 1.38)	0.001	9	5	2.08 (0.70, 6.20)	2.17 (1.00, 2.72)
A4	0.74 (0.47, 1.00)	1.06 (0.71, 1.39)	0.70 (0.61, 0.80)	0.051	35	53	0.57 (0.37, 0.87)	0.81 (0.52, 1.67)
A5	0.53 (0.31, 0.96)	0.78 (0.57, 1.16)	0.68 (0.46, 1.00)	0.071	10	15	0.73 (0.33, 1.62)	1.07 (0.43, 1.54)
A6	0.53 (0.34, 1.00)	0.90 (0.62, 1.33)	0.59 (0.43, 0.81)	0.108	13	10	1.53 (0.67, 3.49)	2.61 (1.07, 2.91)
A7	0.68 (0.48, 0.96)	1.01 (0.74, 1.38)	0.67 (0.49, 0.91)	0.099	11	13	0.94 (0.42, 2.10)	1.41 (0.58, 1.79)
A8	0.76 (0.43, 1.17)	0.63 (0.42, 1.00)	1.19 (0.83, 1.72)	0.012	15	24	0.49 (0.26, 0.93)	0.41 (0.20, 1.22)
A9	0.64 (0.43, 1.02)	1.05 (0.81, 1.48)	0.61 (0.49, 0.76)	0.16	2	6	0.32 (0.07, 1.61)	0.53 (1.00, 2.72)
A10	0.70 (0.60, 0.91)	0.98 (0.86, 1.10)	0.71 (0.65, 0.78)	0.201	44	65	0.58 (0.39, 0.85)	0.81 (0.56, 1.75)
A11	0.80 (0.57, 1.20)	1.14 (0.93, 1.53)	0.71 (0.52, 0.95)	0.112	4	11	0.51 (0.16, 1.66)	0.72 (1.00, 2.72)
A12	0.68 (0.49, 1.11)	0.91 (0.59, 1.36)	0.74 (0.64, 0.87)	0.036	36	58	0.52 (0.34, 0.79)	0.70 (0.46, 1.58)
A13	0.75 (0.52, 1.05)	1.03 (0.75, 1.42)	0.73 (0.68, 0.77)	0.065	327	359	0.87 (0.75, 1.01)	1.20 (1.02, 2.78)
A14	0.70 (0.47, 1.06)	0.99 (0.78, 1.33)	0.71 (0.62, 0.81)	0.093	27	46	0.53 (0.33, 0.85)	0.75 (0.46, 1.58)
A15	0.71 (0.47, 1.05)	0.97 (0.69, 1.41)	0.73 (0.68, 0.79)	0.057	187	218	0.80 (0.66, 0.97)	1.10 (0.91, 2.48)
B1	0.77 (0.44, 1.42)	1.51 (0.78, 2.57)	0.51 (0.42, 0.62)	0.083	116	70	0.79 (0.59, 1.06)	1.55 (1.11, 3.02)
B16	1.01 (0.60, 1.77)	1.23 (0.73, 2.27)	0.82 (0.67, 1.01)	0.011	34	32	1.17 (0.72, 1.90)	1.41 (0.82, 2.27)
B17	1.16 (0.69, 1.59)	1.04 (0.66, 1.68)	1.12 (0.79, 1.58)	0.004	11	18	0.66 (0.31, 1.40)	0.59 (0.26, 1.30)
B15	0.71 (0.47, 1.05)	0.97 (0.68, 1.36)	0.73 (0.68, 0.79)	0.061	187	229	0.76 (0.63, 0.93)	1.04 (0.85, 2.34)
C1	0.77 (0.42, 1.43)	1.07 (0.61, 1.91)	0.72 (0.62, 0.83)	0	255	73	0.94 (0.76, 1.17)	1.32 (0.68, 1.97)
C16	0.97 (0.55, 1.71)	1.28 (0.76, 2.27)	0.76 (0.62, 0.93)	0.012	48	18	0.78 (0.48, 1.28)	1.03 (0.62, 1.86)
C18	0.85 (0.67, 1.20)	0.93 (0.67, 1.22)	0.92 (0.82, 1.03)	0.004	34	38	0.81 (0.55, 1.19)	0.88 (0.59, 1.80)
C19	0.84 (0.63, 1.23)	0.93 (0.64, 1.42)	0.90 (0.76, 1.08)	0.005	74	70	0.91 (0.66, 1.25)	1.01 (0.73, 2.07)
C20	0.82 (0.59, 1.24)	0.96 (0.67, 1.41)	0.89 (0.76, 1.03)	0.014	44	42	0.97 (0.63, 1.48)	1.09 (0.69, 2.00)
D18	0.85 (0.67, 1.15)	0.96 (0.70, 1.26)	0.87 (0.78, 0.97)	0.011	27	45	0.71 (0.48, 1.06)	0.82 (0.54, 1.72)
D19	0.83 (0.64, 1.15)	0.95 (0.68, 1.27)	0.85 (0.72, 1.01)	0.013	67	77	0.90 (0.66, 1.24)	1.06 (0.75, 2.12)

Supplemental Table 8: Treatment Effect on Change in Urine Protein and on Clinical Outcome (ESRD, Doubling and Death) (continued)

E21	0.82 (0.51, 1.28)	0.79 (0.53, 1.23)	1.04 (0.85, 1.27)	0.001	17	29	0.48 (0.26, 0.87)	0.46 (0.25, 1.28)
E22	0.42 (0.22, 0.86)	0.49 (0.27, 0.91)	0.88 (0.66, 1.19)	0.004	22	24	1.00 (0.55, 1.83)	1.14 (0.59, 1.81)
E23	0.30 (0.13, 0.80)	0.50 (0.28, 1.05)	0.61 (0.48, 0.79)	0.043	13	28	0.41 (0.21, 0.80)	0.68 (0.35, 1.42)
A ^b	0.72 (0.49, 1.05)	0.96 (0.69, 1.38)	0.73 (0.67, 0.81)		847	1038	0.76 (0.67, 0.85)	0.96 (0.81-1.13)
B ^b	0.79 (0.48, 1.27)	1.10 (0.69, 1.67)	0.73 (0.61, 0.87)		348	349	0.79 (0.66, 0.92)	1.17 (0.89-1.52)
C ^b	0.83 (0.54, 1.33)	1.04 (0.67, 1.63)	0.83 (0.72, 0.96)		455	241	0.90 (0.76, 1.05)	1.08 (0.86-1.38)
D ^b	0.82 (0.63, 1.15)	0.95 (0.68, 1.33)	0.86 (0.69, 1.09)		94	122	0.82 (0.63, 1.07)	0.95 (0.66-1.36)
E ^b	0.44 (0.23, 1.00)	0.56 (0.32, 1.13)	0.83 (0.66, 1.03)		52	81	0.60 (0.41, 0.84)	0.69 (0.46-1.08)

^a GMR, geometric mean ratio between the early follow-up and baseline geometric mean UP, urine protein levels; CI, confidence interval; HR, hazard ratio.

^b Shown are pooled estimates under Bayesian mixed models and 95% posterior credible intervals.

Urine protein was log transformed in statistical analyses.

A is RAS (renin angiotensin system) Blockade vs. Control, **B** is RAS Blockade vs. CCB (calcium channel blocker), **C** is Intensive Blood Pressure **D** is Low protein diet, and **E** is Immunosuppressive therapy.

Each study is referred by an alphanumeric code. Each letter refers to treatment comparisons, and each number refers to the individual studies. **A** is RAS (renin angiotensin system) Blockade vs. Control, **B** is RAS Blockade vs. CCB (calcium channel blocker), **C** is Intensive Blood Pressure **D** is Low protein diet, and **E** is Immunosuppressive therapy. For studies with multiple interventions, there will be multiple letter-number codes for that study. For example, AASK which had multiple interventions: RAS Blockage vs. placebo, RAS Blockade vs. CCB, and Blood pressure control. Its study number is 1, but it has three codes to indicate the specific treatment comparison: A1, B1 and C1.